Abstract 183P
Background
Personalized targeted cancer treatment strongly depends on genetic tests in tumor tissue. Meanwhile, it is essential to understand the oncogenicity of a large number of somatic and germline variants to identify potential drug targets, which can be used for further treatment. An adopted classification scheme to guide variant oncogenicity assessment has to be easy, fast and reproducible. In this study we implemented a full-fledged database SomaVar and web-based frontend for somatic variant upload, annotation and classification using the VICC classification guidelines.
Methods
The frontend provides a multitude of utility functions which include an advanced variant search, user defined variant lists, automatic classification criteria selection and extensive administrative utilities. SomaVar supports variant annotation including in-silico pathogenicity prediction scores, splicing prediction scores, third party classifications, population scores and protein domains. SomaVar has a semi-automatic classification algorithm for oncogenicity based on the VICC standards and allows harmonized consensus classification between different users.
Results
Using a list of variants already classified by experts we show that the automatic classification algorithm provides a high-quality preselection for most VICC criteria. This not only increases the speed at which experts can classify variants, but also increases quality by mitigating human error. We also compared our knowledgebase to OnkoKB. A large overlap was found within the both groups of variants of likely oncogenic and of unclear oncogenicity variants. Interestingly, divergent classification was observed for variants located within splice regions and for benign variants listed in gnomAD at high allele frequencies.
Conclusions
To date, our knowledgebase harbors over 20.000 classified somatic variants and continues to grow. This open-source knowledgebase is publicly available online.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
25P - Feasibility of digital spatial profiling as a diagnostic: Comparison to immunohistochemistry (IHC)
Presenter: Hannah Hibbs
Session: Cocktail & Poster Display session
Resources:
Abstract
26P - Predictive biomarker discovery for ICI treatment response in metastatic MMRd endometrial cancer through deep proteomic profiling of FFPE tissue samples
Presenter: Juan Francisco Grau-Béjar
Session: Cocktail & Poster Display session
Resources:
Abstract
27P - Analytical validation of a small amplicon NGS panel for MSI detection
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
28P - Clinical significance of TROP2 expression in lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
29P - PTEN/CREBBP/NOTCH1 co-alterations with TP53/RB1 define molecular subtypes associated with primary therapy resistance in small cell lung cancer (SCLC)
Presenter: Louisa Hempel
Session: Cocktail & Poster Display session
Resources:
Abstract
30P - Role of suppressor of cytokine signalling 6 (SOCS6) in colorectal cancer pathogenesis: Integrating clinical and molecular perspectives
Presenter: Asma Al- Bahri
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Adult granulosa cell tumours of ovary: Analysis of 227 non-recurrent and recurrent cases
Presenter: Jan Hojný
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Clinical evaluation cancer testis antigen 45 (CT45) expression in ovarian cancer
Presenter: Harshita Dubey
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Molecular-genetic concordance of the primary tumor and brain metastases of colorectal cancer (GENCONCOR-1)
Presenter: David Halafyan
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - A prognostic signature to predict recurrence in patients with residual disease in triple-negative breast cancer: NACATRINE trial
Presenter: Ana Julia de Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract